Cargando…

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)

Dulaglutide (DU) approved at doses of 0.75 and 1.5 mg once-weekly is an effective glucose lowering agent for treatment of type 2 diabetes (T2D). We hypothesized that higher investigational DU doses may provide further improvements in glucose control and body weight (BW) with an acceptable safety pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frias, Juan Pablo, Ruiz, Luis Nevárez, Li, Ying Grace, Yu, Zhuoxin, Milicevic, Zvonko, Woodward, Brad, Cox, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209020/ http://dx.doi.org/10.1210/jendso/bvaa046.2057

Ejemplares similares

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
por: Bonora, Enzo, et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
por: Ghosh, Aneesh
Publicado: (2021)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

MON-681 Dulaglutide Commonly Known as Trulicity; An Anti-Diabetic Medication Causing Small Bowel Obstruction
por: Gandhi, Ankita, et al.
Publicado: (2020)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

OR08-04 Differences in Advanced Lipoprotein Profile Between Rabson-Mendenhall Syndrome and Lipodystrophy
por: Al-Jundi, Mohammad, et al.
Publicado: (2020)

OR08-05 Sex and Ethnic Differences in Advanced Lipoprotein Profiles in South Asians, African-Americans, and Caucasians
por: Sarcone, Camila, et al.
Publicado: (2020)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

OR08-06 Increased Carotid Intima Media Thickness in Pediatric Type 1 Diabetes Is Associated with Disease Duration
por: Cohen, Michal, et al.
Publicado: (2020)

OR08-03 Association of Hemoglobin A1c with Early Postpartum Metabolic Syndrome in Women with Gestational Diabetes
por: Blair, Rachel A, et al.
Publicado: (2020)

SUN-683 Was Metformin the Culprit for This Lactic Acidosis?
por: Vemparala, Pranathi, et al.
Publicado: (2020)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

OR08-02 Do OGTT-based Insulin Secretory Response Measures Approximate 1(st) Phase Insulin Response in Pregnant Women?
por: Powe, Camille Elise, et al.
Publicado: (2020)

A Rare Case of Metformin Associated Lactic Acidosis in a Type 2 Diabetic Patient With No Known Contraindications for Metformin Prescription - a Diagnostic Conundrum!
por: Gandhi, Rima, et al.
Publicado: (2021)

OR08-01 One-Step Versus Two-Step Approach for Gestational Diabetes Mellitus Screening: Comparison of Maternal and Fetal Outcomes in a Canadian Population
por: Goyette, Fanny, et al.
Publicado: (2020)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

SAT-LB030 Efficacy of Combined Therapy with Metformin and Sitagliptin in Patients with Type 2 Diabetes Who Did Not Reach Target Levels of Glycated Hemoglobin on Metformin Monotherapy
por: Klitsunova, Yuliia, et al.
Publicado: (2019)

Association Between Metformin and Prevention of Dementia in T2DM Adult Patients
por: dos Santos, Natalia Moles, et al.
Publicado: (2021)

SAT-148 Vitamin B12 Deficiency Among Patients with Metformin and Diabetic Neuropathy.
por: Alvarez, Mauricio, et al.
Publicado: (2019)

SUN-695 Should Vitamin B12 Status Monitoring Be Implemented for Patients Taking Metformin?
por: Hoskyns, Wesley, et al.
Publicado: (2020)

SUN-175 Severe Lactic Acidosis Due to Intentional Suicide Attempt with Metformin and Its ICU Management
por: Motazedi, Banafsheh
Publicado: (2019)

Is Metformin Use Associated With a Decreased Mortality for COVID-19 Diabetic Patients? A Meta-Analysis
por: Sun, Chenyu, et al.
Publicado: (2021)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

MON-621 Prescription Analysis Shows High Metformin Use and Acceptance in a Diabetes Specialty Centre in Eastern India
por: Mishra, Sanat Kumar, et al.
Publicado: (2020)

Effects of Exercise, Metformin, Pioglitazone and Exenatide Treatment on Inflammation Induced Insulin Resistance and Ubiquitin Proteasome System in Diabetes and Obesity
por: Akarsu, Ersin, et al.
Publicado: (2021)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

SAT-LB128 A Case of Metformin Associated Lactic Acidosis and the Importance of Medication Reconciliation in End-Stage Renal Disease
por: Tsai, Karen, et al.
Publicado: (2020)

FRI646 Dulaglutide-induced Acute Liver Injury - A Case Report
por: Shahid, Maham, et al.
Publicado: (2023)

MON-LB113 Insulin Resistance in Type 1 Diabetes Managed With Metformin (INTIMET): Rationale and Study Design of a Randomised Placebo-Controlled Trial
por: Snaith, Jennifer R, et al.
Publicado: (2020)

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
por: Fazeli, Sasan, et al.
Publicado: (2019)

SAT-LB126 Metformin Attenuates Sodium Retention and Blood Pressure in Hypertensive Diabetic Mice by Reducing the Phosphorylation of Renal NCC and Its Association With the Actin Cytoskeleton
por: Gholam, Mohammed F, et al.
Publicado: (2020)

OR05-1 Genetic Discovery and Translational Decision Support from Exome Sequencing of 45,231 Type 2 Diabetes Cases and Controls from Five Ancestries
por: Udler, Miriam, et al.
Publicado: (2019)

Identification of Sortilin Alternatively Spliced Variants in 3T3L1 Adipocytes
por: Lui, Ashley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3j8f0qeqv30giopc2h1onc9e74